IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients

计划入组 80 人 · 首次发布于 2024 年 8 月 16 日

Targeting IL-17A for Treatment-Resistant Depression

计划入组 7 人 · 首次发布于 2021 年 7 月 28 日

Changes in Salivary Asprosin, IL-39, IL-40 and IL-1β Levels in Diabetic Patients with Periodontitis

计划入组 176 人 · 首次发布于 2024 年 12 月 16 日

compound amino acid(17aa-ii)

IL-17F/IL-17A capture agents

IL-17A targeting

Simcha Il 18, Inc.

United States

Alliance Foundation Trials, LLC

United States

UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA

Italy

Zenas BioPharma Initiates Phase 1 Trial of ZB021, First Oral IL-17 Inhibitor for Autoimmune Diseases

Zenas BioPharma Secures Global Rights to Orelabrutinib BTK Inhibitor for Multiple Sclerosis in $2+ Billion Deal

Landmark Clinical Trials Demonstrate Efficacy of IL-13 and IL-4/IL-13 Inhibitors in Patients with Darker Skin Tones